GDR — Genedrive Share News
0.000.00%
Last trade - 00:00- £17.66m
- £17.77m
- £0.95m
Welsh hospitals extend routine MT-RNR1 testing
ShareSoc Investor Presentation Reminder
Director/PDMR Notification
Board Appointments
ShareSoc Investor Presentation
Completion of PALOH-UK Patient Recruitment
MT-RNR1 test implemented in the Netherlands
New UK clinical guideline for MT-RNR1 testing
Brief: genedrive Appoints Graham Cole As Chair
Board Appointment
Brief: Genedrive Expects FY26 Revenue Of £1.4 Million In Line With Board Expectations
Trading Update
UK Minister highlights pharmacogenetic testing
Board change
CYP2C19 Agreement with Thermo Fisher Scientific
Brief: Genedrive Says Ian Gilham To Step Down As Chairman & Director By End Of June 2026
Board Changes
Holding(s) in Company
Sussex NHS Trust transitions MT-RNR1 test to BAU